hVIVO plc (LON:HVO - Get Free Report) was down 53.8% during trading on Friday . The stock traded as low as GBX 6.50 ($0.09) and last traded at GBX 7.48 ($0.10). Approximately 41,193,648 shares changed hands during trading, an increase of 1,265% from the average daily volume of 3,018,119 shares. The stock had previously closed at GBX 16.20 ($0.22).
Wall Street Analysts Forecast Growth
Separately, Shore Capital restated a "buy" rating on shares of hVIVO in a research note on Friday.
Read Our Latest Report on hVIVO
hVIVO Stock Performance
The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The firm's 50 day simple moving average is GBX 15.98 and its 200 day simple moving average is GBX 17.81. The firm has a market capitalization of £73.59 million, a price-to-earnings ratio of 4.29 and a beta of 0.97.
hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings data on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Sell-side analysts forecast that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.
Insider Activity
In other news, insider Yamin Mo' Khan sold 3,062,246 shares of hVIVO stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total transaction of £520,581.82 ($703,774.26). Insiders own 14.03% of the company's stock.
hVIVO Company Profile
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Featured Articles
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
